⌕
10x Genomics · TXG · Nasdaq
Tenet 51 · Mixed
Compare
$54.99−5.50%At closeTenet 51 · Mixed
$54.99−3.20 (−5.50%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

10x Genomics (TXG) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~7.0%/yr (FY21→FY25), net margin −6.8%. Worth your attention in FY25: Share count (+13.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲5.2%
642.8
FY21→FY25CAGR +7.0%/yr
Net income ($M)▲76.2%
−43.5
FY21→FY25CAGR —
Free cash flow ($M)—
130.1
FY21→FY25CAGR —
Diluted EPS▲77.0%
−0.35
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+13.1%

110.3mn → 124.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$5.9M

−52.1% YoY in FY25 · 0.9% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)642.8Revenue−198.9COGS443.9Gross profit−238.6R&D−316.1SG&A−61.0Op income17.4Tax & other−43.5Net income

-7¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~4%FY21FY25

Over this window: gross 84.9% → 69.1%. Net margin -6.8% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
618.6642.8610.8618.7516.4490.5▲5.2%+7.0%
Cost of revenue
173.9198.9196.3209.4120.474.1▲1.3%+28.0%
Gross profit
444.6443.9414.5409.3396.0416.4▲7.1%+1.6%
Research & development
222.5238.6264.7331.3265.7211.8▼9.8%+3.0%
Selling, general & admin
297.7316.1344.3343.3298.3257.6▼8.2%+5.3%
Total operating expenses
516.8504.9609.0674.6564.0468.7▼17.1%+1.9%
Operating incomefeeds ROC rank
−72.2−61.0−194.6−265.3−167.9−52.3▲68.7%—
Other income, net
7.021.116.916.66.0−1.5——
Pretax income
−65.2−39.9−177.7−248.8−162.0−53.7▲77.5%—
Income tax
1.93.64.96.34.04.5▼26.2%−5.2%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−67.1−43.5−182.6−255.1−166.0−58.2▲76.2%—
Per share
Diluted EPSbuyback-sensitive
−0.52−0.35−1.52−2.18−1.46−0.53▲77.0%—
Diluted shares (mn)
130.81124.75120.45117.17113.86110.35▲3.6%+3.1%
Margins
Gross margin61st pct in Healthcare
71.9%69.1%67.9%66.2%76.7%84.9%▲1.2pp−15.8pp
Operating margin
−11.7%−9.5%−31.9%−42.9%−32.5%−10.7%▲22.4pp+1.2pp
Net margin27th pct in Healthcare
−10.8%−6.8%−29.9%−41.2%−32.1%−11.9%▲23.1pp+5.1pp
† TTM = trailing four quarters through 2026-09-30.
FY17 – FY20 · 4 more years
Unlock the full history →
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was 10x Genomics' revenue last fiscal year?

10x Genomics reported revenue of $642.8M in fiscal 2025, up 5.2% from fiscal 2024.

What was 10x Genomics' net income?

10x Genomics reported net income of −$43.5M in fiscal 2025, a net margin of −6.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.